Shopping Cart
Validation for the Determination of Proton-Pump Inhibitors

Validation for the Determination of Proton-Pump Inhibitors

Regular price $1,438.40 Sale price

Compare at $1,728.35

  • ISBN-13: 9781544767093
  • Publisher: CreateSpace Independent Publishing Platform
  • Release Date: Mar 19, 2017
  • Pages: 72 pages
  • Dimensions: 0.17 x 11.0 x 8.5 inches
  • Sales Rank: 0

← Previous Product Next Product →


Proton-pump inhibitors (PPIs) have emerged as the drug class of choice for treating patients with acid-related diseases, including gastro esophageal reflux disease (GERD), duodenal ulcer, and gastric ulcer. PPIs are also effective in treating patients with Barrett’s esophagus and Zollinger-Ellison syndrome. These agents inhibit gastric acid secretion by targeting the gastric acid pump, H+ K+ adenosine triphosphatase (ATPase), in the canalicular membrane of the parietal cell. The regulation of acid secretion is a complex process involving many cell types, hormones, and mediators, but these processes converge in a final common step involving H+ K+ ATPase. As a result, PPIs effectively inhibit acid secretion in a manner independent of the processes that stimulate the parietal cell. Each member of the PPI class omeprazole, lansoprazole, pantoprazole and rabeprazole has been shown to be effective and well tolerated in randomized, controlled clinical trials.

Customer Reviews

We Also Recommend